Compare Summit Therapeutics Inc (SMMT) vs Toronto-Dominion Bank (TD) Price & Performance

Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.

The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.

TD Bank trades at $114.39, up 0.46% with bearish technical signals despite strong earnings beats. The stock shows robust fundamentals with 24.88% net margin and 13.64% ROE, supported by a $10 billion buyback program announced September 2026. Revenue growth accelerated to $61.28 billion in 2025 with profit margins recovering to 33.51%. Analyst consensus leans bullish with 9 buy ratings versus 8 holds and no sell recommendations.

TD presents a compelling value opportunity with reasonable P/E of 17.36 and consistent earnings outperformance. Key risks include declining operating cash flow trends and elevated debt-to-asset ratio of 20.86%. The bank's $108 billion Canadian infrastructure commitment and U.S. branch expansion provide growth catalysts, though technical indicators suggest near-term pressure.